Signals
When Dementia Takes Speech, Trials Must Catch Up
CervoMed has completed enrolment in a Phase IIa study of neflamapimod in nonfluent/agrammatic primary progressive aphasia. The milestone is small, but the unmet need is not.
Duchenne Evidence Moves Into the Muscle
Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Migraine Prevention Gets a Wider Door
Cyclospora Is Spreading. The Food Chain Still Has No Answer.
Indigenous cardiovascular inequity is not a data gap. It is a policy failure
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
Alzheimer’s Trials Are Finally Blood-Gated
Europe Can Forecast Vibrio Risk. It Still Has To Act.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.